Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02339532 | Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status(NeoTOP) | completed | Phase 2 | 86 | UNICANCEROTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT02229084 | Vaccination of High Risk Breast Cancer Patients | completed | Phase 1 / Phase 2 | 58 | University of ArkansasOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT02938442 | Vaccination of Triple Negative Breast Cancer Patients | completed | Phase 1 / Phase 2 | 16 | University of ArkansasOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT03227328 | CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO(KENDO) | completed | Phase 2 | 52 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT01827787 | Eribulin in HER2 Negative Metastatic BrCa | completed | Phase 2 | 83 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 6, 2024 | clinicaltrials |
| NCT00221221 | Physical Activity Promotion in Breast Cancer Survivors | completed | Phase 2 / Phase 3 | 300 | University of AlbertaOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT02980341 | Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 182 | Daiichi Sankyo Co., Ltd.INDUSTRY | 2 | Oct 30, 2024 | clinicaltrials |
| NCT06654570 | Effects of Vaginal Estrogen on Serum Estradiol During Aromatase Inhibitor Therapy in Breast Cancer Patients with Vulvovaginal Atrophy: a Prospective Trial | completed | Phase 2 | 20 | Helsinki University Central HospitalOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT04307329 | Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trial(MIMOSA) | completed | Phase 2 | 12 | The Netherlands Cancer InstituteOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT03345485 | Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.(EDO-S101) | completed | Phase 1 / Phase 2 | 71 | Mundipharma Research LimitedINDUSTRY | 5 | Oct 21, 2024 | clinicaltrials |
| NCT03205761 | Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer(COMETABreast) | completed | Phase 2 | 11 | Spanish Breast Cancer Research GroupOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT03004183 | SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC(STOMP) | completed | Phase 2 | 57 | The Methodist Hospital Research InstituteOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT03164993 | Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer(ALICE) | completed | Phase 2 | 68 | Oslo University HospitalOTHER | 2 | Oct 15, 2024 | clinicaltrials |
| NCT03409198 | Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer(ICON) | completed | Phase 2 | 82 | Oslo University HospitalOTHER | 2 | Oct 15, 2024 | clinicaltrials |
| NCT02187991 | Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer | completed | Phase 2 | 169 | US Oncology ResearchINDUSTRY | 1 | Oct 9, 2024 | clinicaltrials |
| NCT03839823 | Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer(RIGHT Choice) | completed | Phase 2 | 222 | Novartis PharmaceuticalsINDUSTRY | 13 | Oct 9, 2024 | clinicaltrials |
| NCT04664972 | Comparison of TP and TAC Regimens in Neoadjuvant Treatment of TNBC | completed | Phase 2 | 212 | Henan Cancer HospitalOTHER_GOV | 1 | Sep 20, 2024 | clinicaltrials |
| NCT00626106 | QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer | completed | Phase 2 | 156 | NantCell, Inc.INDUSTRY | 9 | Sep 19, 2024 | clinicaltrials |
| NCT01074970 | PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations | completed | Phase 2 | 135 | Hoosier Cancer Research NetworkOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02453737 | A Study of Accelerated 3 Fraction Photon,Proton or Brachytherapy for Early Invasive and Noninvasive Breast Ca | completed | Phase 2 | 170 | Mayo ClinicOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05700669 | Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors | completed | Phase 1 / Phase 2 | 3 | Valerio TherapeuticsINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02431676 | Survivorship Promotion In Reducing IGF-1 Trial(SPIRIT) | completed | Phase 2 | 121 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT02613416 | Denosumab and MRI Breast Imaging(Dmab) | completed | Phase 2 | 42 | Alison StopeckOTHER | 1 | Aug 23, 2024 | clinicaltrials |
| NCT03267316 | A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors(CANFOUR) | completed | Phase 1 / Phase 2 | 167 | Cantargia ABINDUSTRY | 11 | Aug 22, 2024 | clinicaltrials |
| NCT05960201 | Diagnostic Performance of [18F]FES PET/CT for Axillary LN Metastasis in Invasive Lobular Carcinoma | completed | Phase 2 | 23 | Asan Medical CenterOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT03530696 | T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer(T-DM1) | completed | Phase 2 | 55 | University of ArizonaOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT05021900 | Efficacy and Safety of Tenalisib (RP6530), in Patients With Locally Advanced or Metastatic Breast Cancer | completed | Phase 2 | 40 | Rhizen Pharmaceuticals SAINDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT03560531 | A Study of ZN-c5 in Subjects With Breast Cancer | completed | Phase 1 / Phase 2 | 181 | Zeno Alpha Inc.INDUSTRY | 9 | Aug 9, 2024 | clinicaltrials |
| NCT05163106 | Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole(NEOLETRIB) | completed | Phase 2 | 85 | University Hospital, AkershusOTHER | 1 | Aug 2, 2024 | clinicaltrials |
| NCT04464174 | Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer(PATHFINDER) | completed | Phase 2 | 54 | MedSIROTHER | 2 | Jul 26, 2024 | clinicaltrials |
| NCT02053636 | A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer(FINESSE) | completed | Phase 2 | 76 | Institut de Recherches Internationales ServierOTHER | 9 | Jul 25, 2024 | clinicaltrials |
| NCT01471106 | Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer | completed | Phase 2 | 26 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT02981303 | Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer | completed | Phase 2 | 64 | HiberCell, Inc.INDUSTRY | 1 | Jul 9, 2024 | clinicaltrials |
| NCT00542451 | Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer | completed | Phase 2 | 406 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT03395899 | Pre-operative Immunotherapy Combination Strategies in Breast Cancer(ECLIPSE) | completed | Phase 2 | 71 | Queen Mary University of LondonOTHER | 1 | Jun 18, 2024 | clinicaltrials |
| NCT00194714 | Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab | completed | Phase 1 / Phase 2 | 22 | University of WashingtonOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT04408118 | First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC(ATRACTIB) | completed | Phase 2 | 100 | MedSIROTHER | 5 | Jun 4, 2024 | clinicaltrials |
| NCT00204490 | Soy Isoflavones and Breast Cancer Risk Reduction | completed | Phase 2 | 197 | The University of Texas Medical Branch, GalvestonOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT04129216 | The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer | completed | Phase 2 | 30 | Johns Hopkins UniversityOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT01377324 | Molecular Imaging of Fulvestrant Effects on Availability of ER Binding Sites | completed | Phase 2 | 16 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT01988324 | AR and ER Imaging in Metastatic Breast Cancer | completed | Phase 2 | 24 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT00796978 | Trastuzumab in Treating Older Women With Early-Stage Breast Cancer | completed | Phase 2 | 56 | Cynthia Owusu, MDOTHER | 1 | May 1, 2024 | clinicaltrials |
| NCT03887130 | Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer | completed | Phase 2 | 152 | Pierre Fabre MedicamentINDUSTRY | 0 | Apr 30, 2024 | clinicaltrials |
| NCT04742959 | Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 203 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Apr 26, 2024 | clinicaltrials |
| NCT02448420 | Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer(PATRICIA II) | completed | Phase 2 | 73 | SOLTI Breast Cancer Research GroupOTHER | 1 | Apr 18, 2024 | clinicaltrials |
| NCT03703466 | A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer | completed | Phase 2 | 72 | Eli Lilly and CompanyINDUSTRY | 5 | Apr 2, 2024 | clinicaltrials |
| NCT03007979 | Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer | completed | Phase 2 | 55 | Washington University School of MedicineOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT02648477 | Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer | completed | Phase 2 | 30 | City of Hope Medical CenterOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT05112536 | Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer | completed | Phase 2 | 24 | G1 Therapeutics, Inc.INDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT00036868 | Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer | completed | Phase 2 | 90 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Mar 8, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Nov 8, 2024source: clinicaltrials